Atuliflapon

N/A

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameAtuliflapon
Drug Alias NameAZD-5718
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action5-lipoxygenase activating protein inhibitors
Targets5-lipoxygenase activating protein
Therapy Area/IndicationsCoronary Artery DiseaseAcute Coronary SyndromeCardiovascular Diseases +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[29] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstraZeneca global R & D (China) Co Ltd
Inactive CompaniesNational University Heart Centre, Singapore
Active IndicationsKidney DiseasesAsthma
Inactive IndicationsCoronary Artery DiseaseAcute Coronary SyndromeCardiovascular Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A